VC Fonds Technologie Berlin
VC Fund
Berlin, Germany
VC Fonds Technologie Berlin is a VC fund in Berlin focused on Software and Health Care. VC Fonds Technologie Berlin GmbH is a joint initiative of Investitionsbank Berlin (IBB) and the State of Berlin.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries VC Fonds Technologie Berlin invests in
SoftwareHealth CareAutomotiveTherapeuticsBiotechnology
Stages VC Fonds Technologie Berlin invests in
SeedSeries ASeries CSeries DFunding Round
Countries VC Fonds Technologie Berlin invests in
GermanyUnited States
Investment Focus
Industry
- Software 3 (23%)
- Health Care 3 (23%)
- Automotive 2 (15%)
- Therapeutics 2 (15%)
- Biotechnology 2 (15%)
Stage
- Seed 3 (23%)
- Series A 3 (23%)
- Series C 2 (15%)
- Series D 2 (15%)
- Funding Round 2 (15%)
Country
- Germany 9 (69%)
- United States 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mika
|
Mika is a digital platform that empowers cancer patients. It aims to help improve cancer patients' mental health and well-being. Mika was created in collaboration with leading research institutions. The company was established in 2017 and is headquartered in Berlin, Germany. | Seed / Aug 06, 2019 | |
German Autolabs
|
German Autolabs empowers mobile workers in logistics with voice assistance, increasing efficiency and improving quality of service in many transport industries. Their unique modular technology can be deployed in driver apps, scanners and vehicles. German Autolabs builds industry-specific solutions that augment daily workflows of professionaldrivers, couriers and delivery staff. Their assistant skills speak the language of logistics and are used by leading providers around the world. | $7.7M / Seed / Feb 18, 2019 | |
OMEICOS Therapeutics
|
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $18.6M / Series C / Nov 02, 2018 | |
Contentflow
|
Contentflow is the global Next-Gen SaaS solution for multichannel, independent live streaming for events, conferences and media coverage. Contentflow develops software for video-livestreaming your event in flawless quality to any mobile and stationary device available. | $2.2M / Seed / Oct 29, 2018 | |
Thermondo
|
Thermondo promote the energy transition with innovative heat solutions.Directly to the customer, providing superior energy products. Thermondo is a an integrated energy company offering state-of-the-art energy efficiency services. Thermondo became the largest installer of heating solution in Germany applying digital process excellence and qualitymanagement. They believe in deep vertical integration in order to achieve market disrupting quality and an outstanding customer experience. | $23M / Series D / Nov 03, 2017 | |
|
OMEICOS Therapeutics
|
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $9.1M / Series B / Mar 01, 2017 | |
Eternygen
|
Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen’s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseaseswith dramatically increasing prevalences in the last decades. Eternygen’s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity.Company’s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure. | $8.8M / Series A / Jan 09, 2017 | |
Meetrics
|
Since 2008 Meetrics provides cutting edge solutions to master online marketing across all channels, creating a transparent and a more efficient digital eco-system. The key areas Meetrics focuses on are: Viewability, Fraud Prevention, Brand Safety and Audience Verification. As the first European vendor Meetrics is being accredited by the mostrelevant industry committee, the MRC, for both measuring Display and Video Ads. | Sep 13, 2016 | |
Babble
|
Babble is a magazine and online community site that offers information and lifestyle content for urban hipsters. It covers beauty, home, food, travel, entertainment, parenting, and more. Babble was founded by Alisa Volkman and Rufus Griscom in December 2006 and is based in New York, USA. | $22M / Series C / Jul 08, 2015 | |
|
OMEICOS Therapeutics
|
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $6.8M / Series A / Apr 15, 2015 | |
| See all 13 investments → | |||
Co-Investors
KfW
4 deals together
HTGF (High-Tech Gruenderfonds)
3 deals together
SMS Group
3 deals together
Vesalius Biocapital Partners
3 deals together
IBB Ventures
2 deals together
The Falck Revocable Trust
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Transportation Investors
27,893 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Automotive Investors
10,535 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does VC Fonds Technologie Berlin invest in?
VC Fonds Technologie Berlin invests primarily in Software, Health Care and Automotive startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did VC Fonds Technologie Berlin last invest?
The most recent investment recorded for VC Fonds Technologie Berlin closed in Aug 2019. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
